-
公开(公告)号：US20180339986A1
公开(公告)日：2018-11-29
申请号：US16051879
申请日：2018-08-01
Applicant: FORMA Therapeutics, Inc.
Inventor： Alexandre Joseph Buckmelter , Stephanos Ioannidis , Bruce Follows , Gary Gustafson , Minghua Wang , Justin A. Caravella , Zhongguo Wang , Edward L. Fritzen , Jian Lin
IPC: C07D473/00 , A61K31/522
CPC classification number: C07D473/00 , A61K31/522
Abstract: The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: where R1, R2, R3, R3′, R4, R5, X1, X2, X3, X4, and n are described herein.
-
52.发明申请公开(公告)号：US20180312487A1
公开(公告)日：2018-11-01
申请号：US15964844
申请日：2018-04-27
Applicant: FORMA Therapeutics, Inc.
Inventor： Jian Lin , Anna Ericsson , Ann-Marie Campbell , Gary Gustafson , Zhongguo Wang , R. Bruce Diebold , Susan Ashwell , David R. Lancia, JR. , Justin Andrew Caravella , Wei Lu
IPC: C07D401/12 , C07D471/04 , C07D401/14 , A61K31/47
CPC classification number: C07D401/12 , A61K31/47 , A61P35/00 , C07D401/14 , C07D471/04
Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
-
Patent Agency Ranking
公开(公告)号：US09815817B2
公开(公告)日：2017-11-14
申请号：US14858165
申请日：2015-09-18
Applicant: Forma Therapeutics, Inc.
Inventor： Jian Lin , Anna Ericsson , Ann-Marie Campbell , Gary Gustafson , Zhongguo Wang , R Bruce Diebold , Susan Ashwell , David R. Lancia, Jr. , Justin Andrew Caravella , Wei Lu
IPC: C07D401/14 , C07D405/14 , C07D413/14 , C07D401/12 , C07D409/14 , C07D417/14 , C07D471/04 , A61K31/506 , C07D403/12
CPC classification number: C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R6 are described herein.
-
54.发明申请QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS 有权喹诺酮五元杂环化合物作为突变型脱氢酶抑制剂公开(公告)号：US20160311818A1
公开(公告)日：2016-10-27
申请号：US14858153
申请日：2015-09-18
Applicant: Forma Therapeutics, Inc.
Inventor： Jian Lin , Anna Ericsson , Ann-Marie Campbell , Gary Gustafson , Zhongguo Wang , R. Bruce Diebold , Susan Ashwell , David R. Lancia, Jr. , Justin Andrew Caravella , Wei Lu
IPC: C07D471/04 , C07D417/14 , C07D417/12
CPC classification number: C07D417/12 , A61P35/00 , C07D417/14 , C07D471/04
Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where Y1, X1, X2, Y2, W1, W2, W3, and R1-R5 are described herein.
Abstract translation: 其中描述了Y1，X1，X2，Y2，W1，W2，W3和R1-R5。
-
55.发明申请PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS 有权吡啶基喹啉酮衍生物作为突变型脱氢酶抑制剂公开(公告)号：US20160083367A1
公开(公告)日：2016-03-24
申请号：US14858170
申请日：2015-09-18
Applicant: Forma Therapeutics, Inc.
Inventor： Jian Lin , Anna Ericsson , Ann-Marie Campbell , Gary Gustafson , Zhongguo Wang , R. Bruce Diebold , Susan Ashwell , David R. Lancia, JR. , Justin Andrew Caravella , Wei Lu
IPC: C07D401/12 , C07D401/14 , C07D417/14 , C07D413/14
CPC classification number: C07D401/12 , A61K31/4704 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.
Abstract translation: 本发明涉及用于治疗细胞增殖障碍和癌症的具有新形态活性的突变异柠檬酸脱氢酶（mt-IDH）蛋白的抑制剂，其具有下式：其中A，B，U，V，Z，W1，W2，W3 ，和R1-R6。
-
56.发明申请PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS 有权吡啶-2（1H） - 酮喹诺酮衍生物作为突变型脱氢酶抑制剂公开(公告)号：US20160083366A1
公开(公告)日：2016-03-24
申请号：US14858167
申请日：2015-09-18
Applicant: Forma Therapeutics, Inc.
Inventor： Jian Lin , Anna Ericsson , Ann-Marie Campbell , Gary Gustafson , Zhongguo Wang , R. Bruce Diebold , Susan Ashwell , David R. Lancia, JR. , Justin Andrew Caravella , Wei Lu
IPC: C07D401/12 , C07D471/04 , C07D401/14
CPC classification number: C07D401/12 , A61K31/47 , C07D401/14 , C07D471/04
Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
Abstract translation: 本发明涉及具有用于治疗细胞增殖障碍和癌症的具有新形态活性的突变异柠檬酸脱氢酶（mt-IDH）蛋白的抑制剂，其具有下式：其中A，U，W1，W2，W3，R1-R6和 R9在本文中描述。
-
57.发明申请QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS 有权喹诺酮类吡啶类组合物作为突变型脱氢酶抑制剂公开(公告)号：US20160083365A1
公开(公告)日：2016-03-24
申请号：US14858165
申请日：2015-09-18
Applicant: Forma Therapeutics, Inc.
Inventor： Jian Lin , Anna Ericsson , Ann-Marie Campbell , Gary Gustafson , Zhongguo Wang , R Bruce Diebold , Susan Ashwell , David R. Lancia, JR. , Justin Andrew Caravella , Wei Lu
IPC: C07D401/12 , C07D401/14 , C07D403/12 , C07D413/14 , C07D471/04 , C07D409/14 , C07D405/14 , C07D417/14
CPC classification number: C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R6 are described herein.
Abstract translation: 本发明涉及用于治疗细胞增殖障碍和癌症的具有新形态活性的突变异柠檬酸脱氢酶（mt-IDH）蛋白的抑制剂，其具有下式：其中A，B，W1，W2，W3和R1-R6是 在此描述。
-
-
-
-
-
-
Search Results
57
records
(took 0.056 seconds)
